Wells Fargo
NBIX icon

Wells Fargo’s Neurocrine Biosciences NBIX Stock Holding History

Wells Fargo’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-25,000
Closed -$235K – 6591
2019
Q2 		$235K Buy
+25,000
New +$2.05M ﹤0.01% 4884

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo's NBIX Position: Q1 2026 in Review

Wells Fargo reduced its Neurocrine Biosciences (NBIX) stake by 4.5% in Q1 2026, selling an estimated $1.43M and leaving 231,311 shares worth $30.5M. The position accounts for 0.01% of the portfolio, ranked #1244.

Wells Fargo first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $127M in Q3 2018. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Wells Fargo held 231,311 shares of Neurocrine Biosciences worth $30.5M as of Q1 2026.
  • Wells Fargo sold 10,800 Neurocrine Biosciences shares in Q1 2026, an estimated $1.43M.
  • Neurocrine Biosciences made up 0.01% of Wells Fargo's portfolio in Q1 2026, its #1244 holding.
  • Wells Fargo first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's Neurocrine Biosciences position peaked at $127M in Q3 2018.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.